See more : Meiwa Estate Company Limited (8869.T) Income Statement Analysis – Financial Results
Complete financial analysis of MedMira Inc. (MMIRF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedMira Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- RiskOn International, Inc. (ROI) Income Statement Analysis – Financial Results
- Hongkong Land Holdings Limited (HKLD.L) Income Statement Analysis – Financial Results
- MGC Ventures, Inc. (MGCV) Income Statement Analysis – Financial Results
- Corning Incorporated (GLW) Income Statement Analysis – Financial Results
- Bergs Timber AB (publ) (0H2W.L) Income Statement Analysis – Financial Results
MedMira Inc. (MMIRF)
About MedMira Inc.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. In addition, the company offers VYRA CoV2 that detects antigens specific for the nucleocapsid region of SARS-CoV-2; VYRA CoV2Flu, a combination viral nucleocapsid antigen tests that detects infection caused by SARS-CoV-2, and Influenza A and Influenza B; and REVEALCOVID-19, an antibody test. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 412.57K | 432.53K | 952.13K | 2.14M | 919.07K | 527.45K | 588.87K | 747.34K | 2.26M | 4.05M | 2.53M | 2.00M | 970.63K | 909.87K | 1.07M | 1.14M | 1.52M | 1.71M | 2.09M | 2.66M | 2.44M | 1.18M | 114.65K | 373.68K | 78.43K |
| Cost of Revenue | 186.08K | 132.15K | 648.10K | 422.73K | 346.79K | 104.09K | 127.76K | 269.05K | 1.24M | 2.87M | 1.75M | 1.37M | 376.40K | 493.91K | 338.15K | 580.24K | 986.30K | 906.33K | 950.08K | 1.57M | 1.15M | 749.84K | 448.08K | 342.24K | 28.33K |
| Gross Profit | 226.49K | 300.38K | 304.03K | 1.72M | 572.28K | 423.35K | 461.11K | 478.30K | 1.02M | 1.18M | 774.80K | 630.78K | 594.24K | 415.96K | 735.02K | 557.41K | 538.22K | 798.99K | 1.14M | 1.09M | 1.29M | 426.66K | -333.44K | 31.44K | 50.10K |
| Gross Profit Ratio | 54.90% | 69.45% | 31.93% | 80.29% | 62.27% | 80.26% | 78.30% | 64.00% | 45.16% | 29.13% | 30.65% | 31.52% | 61.22% | 45.72% | 68.49% | 49.00% | 35.30% | 46.85% | 54.57% | 40.83% | 52.70% | 36.27% | -290.84% | 8.41% | 63.88% |
| Research & Development | 476.89K | 470.68K | 191.14K | 359.32K | 199.27K | 317.35K | 522.94K | 292.30K | 2.52M | 604.14K | 294.43K | 133.30K | 199.02K | 275.27K | 332.36K | 317.30K | 333.60K | 329.25K | 653.62K | 471.73K | 502.58K | 819.35K | 1.20M | 1.70M | 761.22K |
| General & Administrative | 1.20M | 842.61K | 734.83K | 490.59K | 1.17M | 905.90K | 1.20M | 1.20M | 1.47M | 1.92M | 2.35M | 2.10M | 2.50M | 1.97M | 2.67M | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 661.91K |
| Selling & Marketing | 283.13K | 196.11K | 14.74K | 44.30K | 40.33K | 131.22K | 206.68K | 500.84K | 792.46K | 503.54K | 1.09M | 262.27K | 33.32K | 2.21K | 40.46K | 67.60K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 413.23K |
| SG&A | 1.48M | 1.04M | 749.58K | 534.89K | 1.21M | 1.04M | 1.41M | 1.70M | 2.27M | 2.42M | 3.44M | 2.36M | 2.54M | 1.97M | 2.71M | 2.73M | 3.36M | 3.82M | 5.79M | 4.98M | 3.94M | 3.57M | 3.26M | 4.67M | 1.08M |
| Other Expenses | 843.11K | 735.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.55K | 313.90K | -270.53K | -1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.80M | 2.24M | 1.57M | 1.72M | 1.87M | 1.72M | 2.30M | 2.61M | 5.50M | 3.65M | 4.34M | 2.80M | 2.75M | 2.27M | 3.07M | 3.08M | 3.86M | 4.37M | 6.62M | 5.53M | 4.78M | 4.74M | 4.78M | 6.73M | 3.36M |
| Cost & Expenses | 2.99M | 2.38M | 2.22M | 2.14M | 2.22M | 1.82M | 2.43M | 2.88M | 6.74M | 6.52M | 6.10M | 4.17M | 3.13M | 2.77M | 3.41M | 3.66M | 4.85M | 5.28M | 7.57M | 7.11M | 5.93M | 5.49M | 5.23M | 7.07M | 3.39M |
| Interest Income | -14.00K | 885.52K | 552.04K | 653.30K | 725.63K | 810.42K | 28.00K | 449.89K | 260.00K | 0.00 | 479.82K | 734.60K | -66.02K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 882.41K | 0.00 | 552.04K | 653.30K | 725.63K | 810.42K | 697.17K | 0.00 | 939.56K | 769.19K | 760.71K | 0.00 | 3.79M | 3.60M | 2.40M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 309.55K | 212.90K | 212.30K | 207.80K | 193.17K | 18.86K | 66.77K | 98.79K | 99.79K | 94.08K | 479.82K | -245.46K | 19.33K | 30.11K | 33.55K | 42.08K | 179.18K | 217.70K | 209.40K | 112.60K | 333.84K | 345.69K | 323.96K | 368.26K | 321.51K |
| EBITDA | -2.13M | -1.58M | -1.07M | 185.30K | -1.13M | -1.28M | -1.75M | -2.11M | -4.38M | -2.65M | -2.99M | -2.41M | -2.14M | -1.30M | -2.30M | -2.48M | -3.15M | -3.35M | -5.27M | -4.33M | -3.16M | -3.96M | -4.79M | -6.33M | -2.99M |
| EBITDA Ratio | -517.33% | -364.66% | -112.09% | 8.64% | -122.58% | -242.14% | -296.42% | -282.65% | -182.52% | -58.67% | -122.18% | -120.45% | -220.59% | -142.38% | -214.67% | -218.40% | -211.55% | -196.61% | -251.94% | -162.92% | -129.59% | -337.02% | -4,176.94% | -1,694.50% | -3,806.44% |
| Operating Income | -2.57M | -1.94M | -1.45M | -184.23K | -1.30M | -1.30M | -1.84M | -2.13M | -4.48M | -2.47M | -3.57M | -2.17M | -2.16M | -1.86M | -2.34M | -2.53M | -3.25M | -3.57M | -5.48M | -4.45M | -3.49M | -4.31M | -5.11M | -6.70M | -3.31M |
| Operating Income Ratio | -623.65% | -449.52% | -152.63% | -8.59% | -141.46% | -245.72% | -312.51% | -285.43% | -198.46% | -60.99% | -141.15% | -108.19% | -222.58% | -204.11% | -217.79% | -222.10% | -213.09% | -209.37% | -261.95% | -167.15% | -143.28% | -366.40% | -4,459.52% | -1,793.05% | -4,216.38% |
| Total Other Income/Expenses | -753.33K | -731.34K | -378.35K | -491.57K | -745.23K | -810.42K | -669.17K | -527.90K | -679.54K | -488.09K | -266.72K | 1.76M | 5.74M | -3.07M | 313.90K | -270.53K | -963.43K | 18.56K | 592.00 | 1.21K | 40.69K | 147.93K | 209.91K | 116.63K | 0.00 |
| Income Before Tax | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M | -2.11M | -2.51M | -2.66M | -5.16M | -3.23M | -3.84M | -402.30K | 3.37M | -4.93M | -2.02M | -2.80M | -4.21M | -3.55M | -5.48M | -4.45M | -3.45M | -4.16M | -4.90M | -6.58M | 0.00 |
| Income Before Tax Ratio | -806.25% | -618.61% | -192.37% | -31.51% | -222.55% | -399.37% | -426.15% | -356.07% | -228.57% | -79.70% | -151.70% | -20.10% | 347.43% | -541.75% | -188.54% | -245.87% | -276.29% | -208.29% | -261.93% | -167.11% | -141.61% | -353.83% | -4,276.42% | -1,761.84% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 173.68K | 161.73K | -19.60K | -153.00K | 28.00K | -78.01K | 939.56K | 769.19K | 280.89K | 980.06K | 3.79M | -37.00K | 2.40M | 2.47M | 2.65M | 2.74M | 1.81M | 1.66M | 538.91K | 453.19K | 755.39K | 612.74K | -409.66K |
| Net Income | -3.33M | -2.68M | -1.83M | -675.80K | -2.05M | -2.11M | -2.51M | -2.66M | -5.16M | -3.23M | -3.84M | -402.30K | 3.37M | -4.89M | -4.42M | -5.26M | -7.02M | -6.29M | -7.29M | -6.11M | -3.99M | -4.62M | -5.66M | -7.20M | -2.90M |
| Net Income Ratio | -806.25% | -618.61% | -192.37% | -31.51% | -222.55% | -399.37% | -426.15% | -356.07% | -228.57% | -79.70% | -151.70% | -20.10% | 347.43% | -537.68% | -411.74% | -462.64% | -460.34% | -368.70% | -348.46% | -229.51% | -163.71% | -392.35% | -4,935.31% | -1,925.81% | -3,694.04% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.01 | -0.02 | -0.02 | -0.05 | -0.09 | -0.10 | -0.15 | -0.14 | -0.10 | -0.18 | -0.27 | -0.35 | -0.14 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.01 | -0.02 | -0.02 | -0.05 | -0.09 | -0.10 | -0.15 | -0.14 | -0.10 | -0.18 | -0.27 | -0.35 | -0.14 |
| Weighted Avg Shares Out | 697.67M | 668.91M | 680.65M | 658.33M | 658.36M | 658.36M | 627.52M | 658.36M | 644.80M | 558.36M | 514.36M | 392.26M | 278.99M | 216.59M | 188.20M | 116.45M | 81.88M | 60.99M | 48.59M | 43.62M | 39.93M | 25.26M | 20.96M | 20.48M | 20.48M |
| Weighted Avg Shares Out (Dil) | 697.67M | 697.45M | 680.65M | 658.33M | 658.36M | 658.36M | 658.36M | 658.36M | 658.36M | 558.36M | 514.36M | 392.26M | 411.70M | 216.59M | 188.20M | 116.45M | 81.88M | 60.99M | 48.59M | 43.62M | 40.55M | 25.26M | 20.96M | 20.48M | 20.48M |
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
Update on MedMira's Regulatory Path in Canada and the USA
MedMira Closes New Equity Investment for Future Growth
MedMira Reports Third Quarter Results FY2021
MedMira Reports Second Quarter Results FY2021
Progress Update on MedMira's COVID-19 Product Family
MedMira Announces Product Update
MedMira Reports First Quarter Results FY2021
Source: https://incomestatements.info
Category: Stock Reports